Announcement:

Submit your Center of Excellence Application today!

Read More

Join Our Network

We welcome all qualifying physicians to submit their application to become a Macular Degeneration Association AMD Center of Excellence.

Below are some of the highlighted Optometric criteria for an AMD COE with the MDA accreditation:

  • Facility must meet one of the following:
    • Conducts genetic testing
    • Does dark adaptation testing
    • Sells supplements from the office or online
    • Provides low vision services
  • Have at least three of the following technologies
    • MPOD
    • Fundus Photography
    • OCT/OCT-a
    • Dark Adaptation Testing
    • In office CCTV demonstration
    • Prescribes ForeseeHome® AMD Monitoring program for intermediate dry AMD patients
  • Accomplished at least one of the following:
    • Given a lecture on AMD or low vision at a professional meeting in the last 18 months
    • Published an article on AMD or low vision within the last 18 months
    • Present an AMD talk to a patient group within the last 18 months
    • Fellow in good standing of the ORS
    • Fellow in good standing of AAOptom
    • Fellow in good standing of OWNS
    • Obtained at least 3 hours of COPE approved AMD education in the last 18 months

Below are some of the highlighted Retina criteria for an AMD COE with the MDA accreditation:

  • Physicians treating AMD should be fellowship trained in retina, board certified in ophthalmology, and members in good standing of both American Society of Retina Specialists (ASRS) and American Academy of Ophthalmology (AAO).
  • Facility should have all applicable diagnostic testing equipment available at the physical site:
    • Spectral-domain or swept-source OCT device
    • Fundus photography
    • Autofluorescence
    • Fluorseceein angiogram
    • Diagnostic testing equipment
  • At a minimum, at least 30% of the practice should be AMD patients
  • Participate in a multicenter study investigating a new treatment for AMD
  • Lecture on AMD
  • Author a paper or publication on AMD
  • All physicians agree to have available the following medications:
    • Bevacizumab (Avastin, Genentech)
    • Ranibizumab (Lucentis, Genentech)
    • Aflibercept (Eylea, Regeneron)
    • Brolucizumab-dbll (Beovu, Novartis)
    • Any new anti-vascular endothelial growth factor (VEGF)/similar medication approved by the FDA and Medicare.

Join the Network

Complete and submit your enrollment application by clicking the appropriate link below.

Optometric COE Application Retina Physicians COE Application

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.